American Vision Partners performs revolutionary, micro-invasive, injectable treatment for the full range of glaucoma disease to significantly decrease the dependence of daily eye drops.
American Vision Partners ophthalmology practices are proud to announce the availability of iDose® TR (travoprost intraocular implant) 75 mcg iDose TR is a new, FDA approved treatment that is designed to provide long duration, continuous drug therapy directly inside the eye, helping patients take better control over the elevated eye pressure associated with open-angle glaucoma or ocular hypertension.
More than 3 million people in the United States are affected by Glaucoma, an eye disease caused by increased pressure in the eye and it can also cause damage to the optic nerve which carries visual information from the eyes to the brain. If left untreated, glaucoma can cause permanent damage to the eye, which means vision loss cannot be reversed. Prescription eye drops are the most common treatment for glaucoma, but they can be difficult to administer correctly and can cause uncomfortable or irritating side effects for most patients. High rates of non-compliance and non-adherence to prescription medications contribute to disease progression.
“With iDose TR, we confront the standard practice of relying on topical drops, which may cause unpleasant side effects and be challenging to properly administer multiple times a day,” said Dr.
Christine Funke, surgeon at Barnet Dulany Perkins Eye Center. “By delivering an effective therapy directly inside of the eye, iDose TR is an alternative to prescription eye drops and a hands-free way to keep eye pressure under control. The high rate of efficacy of iDose gives me the confidence to perform a standalone glaucoma procedure knowing many patients will gain freedom from their topical therapy. iDose gives physicians and patients a solution for the huge problem of non-compliance; as a result, glaucoma clinic has become a place with happy grateful patients”, says Dr. Funke. Developed by Glaukos, iDose TR reduces high or elevated pressure within the eye by automatically releasing the same type of medication used for decades in the most commonly prescribed eye drops. During a clinical study, 8 out of 10 patients did not need prescription eye drops 12 months after administration of iDose TR. iDose TR may be particularly beneficial for patients who have difficulty adhering to a daily medication regimen or whose condition is uncontrolled on topical glaucoma medications. “
American Vision Partners is dedicated to providing our patients with the most advanced treatment options available, iDose gives physicians and patients a solution for the huge problem of non-compliance when using drops; as a result, my glaucoma clinic has become a place with happy grateful patients”, says Dr. Funke. “iDose TR represents a significant development in how we can proactively address glaucoma care, and we are proud to be among the first practices to make this therapy available.”
Advantages of iDose® TR
- Sustained Medication Release: Delivers consistent levels of medication, reducing IOP fluctuations.
- Improved Compliance: Eliminates the need for daily eye drops, addressing adherence challenges.
- Minimally Invasive Procedure: Implanted during a quick outpatient procedure with minimal recovery time.
- Reduced Side Effects: By delivering medication directly into the eye, it minimizes common side effects associated with topical treatments.
- Long-Term Efficacy: Clinical studies have shown that approximately 80% of patients remained free from additional glaucoma medications for at least 12 months post-implantation.
About American Vision Partners
American Vision Partners is one of the nation’s largest and fastest-growing eye care physician services organizations. AVP serves communities throughout Arizona, Texas, New Mexico, and Nevada with more than 180 nationally recognized doctors and 120 locations. We partner with the most respected ophthalmology practices in the country and share a best-in-class management system, infrastructure, and technology to provide the highest-quality patient care. Our partner practices, including Barnet Dulaney Perkins Eye Center, Southwestern Eye Center, Retinal Consultants of Arizona, M&M Eye Institute, Wellish Abrams Eye Institute, Southwest Eye Institute, Aiello Eye Institute, Moretsky Cassidy Vision Correction, West Texas Eye Associates, and Vantage Eye Center have on average been in practice for more than 30 years. For more information, please visit www.AmericanVisionPartners.com.
